US/UK/Canada

Share

Pick a time period -
Tags ( Active)

DexTech Medical AB, Bulletin from the Annual General Meeting

Today, October 31, 2024, the Annual General Meeting of DexTech Medical AB was held. All resolutions were passed with the required majority. Resolution on adoption of the income statement and balance sheetThe AGM resolved to adopt the presented income statement and balance sheet. Resolution regarding appropriation of the company's result in accordance with the adopted balance sheetThe AGM resolved to allocate the company's result in accordance with the Board of Directors' proposal, and that no dividend be paid for the financial year 2023/2024. Resolution on discharge from

DexTech Medical AB, Interim report July 1- September 30, 2024

Summary of the first quarter (2024-07-01 – 2024-09-30) · Net sales amounted to MSEK 0,0 (0,0) · Operating profit/loss amounted to MSEK -1,3 (-1,1) · Earnings per share* SEK -0.06 (-0.05) · Cash and cash equivalents at the end of the period amounted to MSEK 17,9 (19,0) * Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 18,485,857. Amounts in brackets refer to the corresponding period last year. Comments from the CEO  The latest results

DexTech Medical AB, Invitation to open Annual General Meeting and notice

On Thursday, October 31, 2024, DexTech Medical AB ("DexTech") will hold its Annual General Meeting. Subject to availability, non-shareholders are also welcome to participate without voting rights. At the meeting, the founders, CEO Anders R Holmberg and Medically Responsible Professor Sten Nilsson, among others, will present the company and the clinical situation regarding prostate cancer and multiple myeloma. There will be an opportunity to ask questions to DexTech's Board of Directors and management. Formal notice of the Annual General Meeting is available further down in this press

DexTech Medical AB: Annual Report 2023-07-01 - 2024-06-30

The Board of Directors and the CEO of Dextech Medical AB (DexTech), org.nr. 556664-6203, with its registered office in Stockholm, hereby submits the Annual Report for the financial year 2023-07-01 - 2024-06-30. For more information about DexTech, please contact: Gösta Lundgren - CFO DexTech Medical AB Phone: +46 (0) 707104788 E-mail: gosta.lundgren@dextechmedical.com  DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The lead candidate is OsteoDex for the treatment of

DexTech Medical AB, Year-end report July 1, 2023 - June 30, 2024

Summary of year-end report Fourth quarter (2024-04-01 – 2024-06-30) · Net sales amounted to SEK 0.0 million (0.0) · Operating profit amounted to SEK -1.6 million (-1.3) · Earnings per share* SEK -0.07 (-0.06) Full year (2023-07-01 – 2024-06-30) · Net sales amounted to SEK 0.0 million (0.0) · Operating profit amounted to SEK -5.5 million (-4.9) · Earnings per share* SEK -0.25 (-0.25) · Cash and cash equivalents at the end of the financial year amounted to SEK 19.0 (25.2) million * Before and after dilution. Earnings per share: Profit for the period divided

DexTech Medical AB announces continued positive results from myeloma study

The Phase 1 study examines the effect of OsteoDex on patients with progressive multiple myeloma (MM). Progressive disease means that the disease progresses and does not respond to existing treatment. The first dose group (3mg/kg) is now ready, and the DMC (Data Monitoring Committee) has approved the start of dose group 2 (6mg/kg). DMC assesses all analysis results to decide on the next higher dose. No side effects related to OsteoDex have been noted. All patients show a decrease in skeletal biomarkers. Three out of four patients have stable disease after completion of treatment (stable = no

DexTech Medical AB, Interim report July 1, 2023 - March 31, 2024

Summary of the third quarter (2024-01-01 – 2024-03-31) · Net sales amounted to MSEK 0,0 (0,0) · Operating profit/loss amounted to MSEK -1,5 (-1,6) · Earnings per share* SEK -0.08 (-0.08) Summary of the nine-month period (2023-07-01 – 2024-03-31) · Net sales amounted to MSEK 0,0 (0,0) · Operating profit/loss amounted to MSEK -3,9 (-3,7) · Earnings per share* SEK -0.18 (-0.19) · Cash and cash equivalents at the end of the period amounted to MSEK 21,1 (27,1) * Before and after dilution. Earnings per share: Profit for the period divided by the average number of

DexTech Medical announces new positive results from the myeloma study

The Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). Progressive disease means that the disease progresses and does not respond to existing treatment. A patient who has shown a sharp reduction in skeletal biomarkers and who has now completed his treatment is found to have stable disease with continued low values of markers that reflect skeletal activity. Stable disease means that the disease does not develop/progress, which is very positive. The company now intends to follow patients with stable disease for up to 2 years after completion

DexTech Medical AB, Half-year report July 1 - December 31, 2023

Correction: Due to MAR label being wrongly included in the report.DexTech Medical AB Half-year report July 1 - December 31, 2023 By "Company" or "DexTech" is meant DexTech Medical AB with organization number 556664-6203. Summary of the second quarter (2023-10-01 – 2023-12-31) · Net sales amounted to MSEK 0,0 (0,0) · Operating profit/loss amounted to MSEK -1,4 (-1,2) · Earnings per share* SEK -0,06 (-0.06) * Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average

DexTech Medical AB, Half-year report July 1 - December 31, 2023

Summary of the second quarter (2023-10-01 – 2023-12-31) · Net sales amounted to MSEK 0,0 (0,0) · Operating profit/loss amounted to MSEK -1,4 (-1,2) · Earnings per share* SEK -0,06 (-0.06) * Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 18,485,857. Amounts in brackets refer to the corresponding period last year. Summary of the first half-year (2023-07-01 – 2023-12-31) · Net sales amounted to MSEK 0,0 (0,0) · Operating profit/loss

DexTech Medical AB announces positive results from the myeloma study

The first test results from patient 1 have been received and show a very strong effect on the marker of osteoclast activity (CTX). The baseline value for CTX decreases by about 80% after 3 doses of OsteoDex. The other values are fairly constant (cf. baseline). Osteoclasts break down bone (resorb) and CTX reflects osteoclast activity that is elevated in multiple myeloma.The Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). The first patient is treated during week 50 at Karolinska University Hospital in Huddinge.  The study includes a

DexTech Medical informs about the myeloma study, the first patient is treated

The Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). The first patient is treated during week 50 at Karolinska University Hospital in Huddinge.The Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). The first patient is treated during week 50 at Karolinska University Hospital in Huddinge.  The study includes a total of 20 patients and will initially be conducted at three hospitals in Sweden: Karolinska University Hospital Huddinge, Uddevalla Hospital and Södersjukhuset in Stockholm.

DexTech Medical AB, Bulletin from the Annual General Meeting

Today, October 31, 2023, the Annual General Meeting of DexTech Medical AB was held. All resolutions were passed with the required majority. Resolution on adoption of the income statement and balance sheetThe AGM resolved to adopt the presented income statement and balance sheet. Resolution regarding appropriation of the company's result in accordance with the adopted balance sheetThe AGM resolved to allocate the company's result in accordance with the Board of Directors' proposal, and that no dividend be paid for the financial year 2022/2023. Resolution on discharge from

DexTech Medical AB, Interim report July 1 - September 30, 2023

Summary of the first quarter (2023-07-01 – 2023-09-30) · Net sales amounted to MSEK 0,0 (0,0) · Operating profit/loss amounted to MSEK -1,1 (-0,8) · Earnings per share* SEK -0.05 (-0.04) · Cash and cash equivalents at the end of the period amounted to MSEK 23,6 (25,2) * Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 18,485,857. Amounts in brackets refer to the corresponding period last year. CEO's comment The company's Phase 1 study

DexTech Medical files a new patent application with the European Patent Office

Dextech has filed a new patent application regarding GMP production (Good Manufacturing Practice) of the company's lead candidate OsteoDex with the European Patent Office (EPO.Org). The application describes a GMP synthesis method on a larger scale that results in a pharmaceutical-grade product as well as OsteoDex use for the treatment of cancer that develops in the bones. The application is of great importance for the Company's planned clinical further development of OsteoDex (phase 3, castration-resistant prostate cancer) together with a major partner. "- A synthesis patent will

DexTech Medical AB, Invitation to open Annual General Meeting and notice

On Tuesday, October 31, 2023, DexTech Medical AB ("DexTech") will hold its Annual General Meeting. Subject to availability, non-shareholders are also welcome to participate without voting rights. At the meeting, the founders, CEO Anders R Holmberg and Medical Director Professor Sten Nilsson, will present the company and the current clinical situation regarding prostate cancer. There will be an opportunity to ask questions to DexTech's board and management. Formal notice of the Annual General Meeting is available further down in this press release. Notification for non-shareholders shall

DexTech Medical AB: Annual Report 2022-07-01 - 2023-06-30

The Board of Directors and the CEO of Dextech Medical AB (DexTech), org.nr. 556664-6203, with its registered office in Stockholm, is hereby authorized to submit an annual report for the financial year 2022-07-01 - 2023-06-30. For more information about DexTech, please contact: Gösta Lundgren - CFO DexTech Medical AB Phone: +46 (0) 707104788 E-mail: gosta.lundgren@dextechmedical.com  DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The main candidate is OsteoDex for

DexTech Medical AB, Year-end report July 1, 2021 - June 30, 2022

Summary of the fourth quarter (2022-04-01 – 2022-06-30) · Net sales amounted to MSEK 0,0 (0,0) · Operating profit/loss amounted to MSEK -1,3 (-2,1) · Earnings per share* SEK -0.06 (-0.11) * Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 18,485,857. Amounts in brackets refer to the corresponding period last year. Summary of the financial year (2021-07-01 – 2022-06-30) · Net sales amounted to MSEK 0,0 (0,0) · Operating profit/loss

DexTech Medical AB Interim report July 1, 2022 - March 31, 2023

Summary of the third quarter (2023-01-01 – 2023-03-31) · Patient recruitment has begun for the Multiple Myeloma study · Net sales amounted to MSEK 0,0 (0,0) · Operating profit/loss amounted to MSEK -1,6 (-1,1) · Earnings per share* SEK -0.08 (-0.06) * Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 18,485,857. Amounts in brackets refer to the corresponding period last year. Summary of the nine-month period (2022-07-01 – 2023-03-31) ·

DexTech Medical AB informs about the myeloma study

The company's Phase 1 study regarding the effect of OsteoDex on patients with multiple myeloma (MM) has been initiated and recruitment of patients has begun.  The study includesr 20 patients and is initially conducted at three hospitals in Sweden: Karolinska Universite hospital Huddinge, Uddevalla Hospital and Södersjukhuset in Stockholm. Another center in Sweden may be connected later. The study is expected to be completed in Q4, 2024.  Principal Investigator (PI) is Dr Katarina Uttervall, MD, PhD, Division of Hematology/HERM, Karolinska UniversityHospital Huddinge. Analysis of main

DexTech Medical AB, Half-year report July 1 - December 31, 2022

Summary of the second quarter (2022-10-01 – 2022-12-31) · Net sales amounted to MSEK 0,0 (0,0) · Operating profit/loss amounted to MSEK -1,2 (-1,1) · Earnings per share* SEK -0.06 (-0.08) * Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 14,920,478. Amounts in brackets refer to the corresponding period last year. Summary of the first half-year (2022-07-01 – 2022-12-31) · Net sales amounted to MSEK 0,0 (0,0) · Operating profit/loss

DexTech Medical decision on allocation regarding incentive programs

At the Annual General Meeting of DexTech AB ("DexTech" or the "Company") on 28 October 2022,  it was resolved to introduce an incentive program ("W 2022  /2025") for pre-selected key employees ("Option Holders").  W 2022/2025 gives Option holders the opportunity to subscribe for warrants in DexTech for market valuet in a directed issue. The Board of Directors of DexTech has now decided on the allocation of W 2022/2025. W 2022/2025 In accordance with the terms, the subscription price for the warrants in the directed issue has previously been set at SEK 0.13 per warrant. Payment must be

DexTech Medical AB, Bulletin from the Annual General Meeting

Today, 28 October 2022, the Annual General Meeting of DexTech Medical AB was held. All decisions were taken by the required majority. Resolution on adoption of the income statement and balance sheetThe AGM resolved to adopt the presented income statement and balance sheet. Resolution on appropriation of the company's earnings in accordance with the adopted balance sheetThe AGM resolved to dispose of the company's earnings in accordance with the Board's proposal, and that no dividendsbe paid for the financial year 2021/202 2. Resolution on discharge from liability for the

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe